KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Other Working Capital Changes (2016 - 2025)

Evolent Health (EVH) has 11 years of Other Working Capital Changes data on record, last reported at $28.7 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 25260.53% year-over-year to $28.7 million; the TTM value through Dec 2025 reached -$1.3 million, up 62.41%, while the annual FY2025 figure was -$1.3 million, 62.41% up from the prior year.
  • Other Working Capital Changes reached $28.7 million in Q4 2025 per EVH's latest filing, up from -$29.8 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $28.7 million in Q4 2025 and bottomed at -$29.8 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is -$1.3 million, with a median of -$279500.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: plummeted 3471.65% in 2022, then surged 25260.53% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.9 million in 2021, then tumbled by 194.88% to -$1.8 million in 2022, then plummeted by 765.74% to -$15.2 million in 2023, then skyrocketed by 99.25% to -$114000.0 in 2024, then soared by 25260.53% to $28.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $28.7 million in Q4 2025, -$29.8 million in Q3 2025, and -$7.9 million in Q2 2025.